48 results about "Therapy resistant" patented technology

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

To provide pharmaceutical combinations of treating a clinical condition, e.g., AML.SOLUTION: A pharmaceutical combination comprising a DHODH inhibitor and an anti-CD38 therapeutic agent such as an anti-CD38 antibody is administered to a subject. The pharmaceutical combination can further comprise one or more additional therapeutic agents.SELECTED DRAWING: Figure 2D

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

The present disclosure provides methods of identifying a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of identifying a subject having a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of carrying out a clinical trial for dupilumab treatment of a disease or condition.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The invention relates to the technical field of medicines, in particular to a composition and application thereof in preparation of antitumor medicines. The composition provided by the invention comprises the PD-1 monoclonal antibody and the emodin, and the emodin improves the anti-tumor function of T cells by improving phospholipid phosphatase secreted by CD8 + T cells. The anti-tumor curative effect of the emodin and the PD-1 monoclonal antibody in the composition is obviously higher than that of the two components which are independently administered, so that the emodin and the PD-1 monoclonal antibody synergistically improve the treatment effect of the PD-1 monoclonal antibody, and a novel treatment strategy is provided for clinical PD-1 monoclonal antibody drug resistance.

The present invention relates to the technical field of diagnostic markers, and in particular to a marker for evaluating the efficacy of PD-1 in treating melanoma and its application. Research conducted in the present invention has shown that extracellular vesicle PD-L2 is associated with the clinical response to anti-PD-1 therapy, and its changes are a more reliable biomarker for predicting the prognosis of melanoma patients receiving anti-PD-1 therapy. The baseline level of PD-L2 on the EV membrane and the dynamic changes of PD-L2 on the EV membrane can serve as predictors of the outcome of melanoma immunotherapy and play an important role in evaluating the prognostic effect.

The invention discloses a biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system based on blood magnesium level, and relates to the technical field of biliary duct cancer immunotherapy prognosis, the biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system comprises four core modules, a blood magnesium detection module uses a full-automatic biochemical analyzer to detect serum magnesium, the serum magnesium is divided into a low magnesium group and a normal blood magnesium group, and synchronous quality control is performed; the clinical data acquisition module acquires multi-dimensional information, and two persons check and complement data; the prognosis analysis module integrates data, and evaluates prognosis through statistical test, survival analysis and subgroup verification; and the result output module generates an encrypted report, visually presents and synchronizes the encrypted report to the electronic medical record system. The serum magnesium is used as a prediction index, the cost is low, the serum magnesium is easy to obtain, the serum magnesium is adaptive to hospital equipment at all levels, the independent prediction value and subgroup consistency are confirmed through rigorous analysis, prognosis can be dynamically updated, individualized suggestions are generated, prediction accuracy and clinical practicability are improved, and biliary duct cancer immunotherapy precision is promoted.

All currently available treatment options for autoimmune encephalitis such as anti-NMDAR encephalitis and anti-LGI1 encephalitis carry substantial potential safety risks. Further, no approved therapies exist for anti-NMDAR encephalitis and anti-LGI1 encephalitis. The invention provides a means for a treatment for autoimmune encephalitis (AIE) such as NMDAR encephalitis and anti-LGI1 encephalitis, comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

The invention discloses a biomarker combination for predicting the curative effect of Evoximab on non-small cell lung cancer and application of the biomarker combination. The biomarker combination comprises NLR, MLR, PLR, ApoE and PD-L1. By integrating conventional blood indexes such as ApoE (participating in lipid metabolism regulation and immune regulation) and NLR (reflecting the whole body inflammation state), a non-invasive and clinically-popularized Evoximab curative effect prediction model is constructed, and the bottleneck problem of biomarker deficiency in bispecific antibody (Evoximab) treatment is solved. And a scientific basis is provided for accurately screening benefited crowds.

Methods and apparatus disclosed treat pain and mobility impairments by applying controlled subatmospheric pressure to skin over muscle tissue or joints during volitional muscle contractions against adaptive therapist resistance. Domes with basal openings sealing against skin perimeters, are evacuated to 13-90% of atmospheric pressure. Some embodiments have 3-10 second contraction intervals repeated at least three times per subatmospheric treatment cycle, before pressure is ramped to ambient pressure over at least 2 seconds. Results are improved range of motion, muscle strength, and pain reduction. Apparatus embodiments include vacuum manifolds, sensors for pressure and tissue distension, and optional integrated electrodes for performing TENS / STIM.

The present invention relates to methods of treating head and neck squamous cell carcinoma (HNSCC), such as metastatic or advanced HNSCC, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met) in addition to a PD-(L)1 axis inhibitor (pembrolizumab) and a platinum-based chemotherapy agent (carboplatin). In particular, the EGFR / c-Met antibody is amivantamab.

The invention discloses a device for treating osteoporosis by compounding electromagnetic field and ultrasonic wave with Disumab, which comprises a base plate, a support bed mattress plate is fixedly mounted on the upper surface of the base plate, a limiting groove is formed in the base plate, and a transmission assembly is movably arranged in the limiting groove. A medicine conveying module, an electromagnetic field generating module and an ultrasonic wave generating module are fixedly arranged on the surface of the transmission assembly, the medicine conveying module, the electromagnetic field generating module and the ultrasonic wave generating module are electrically connected with an external control module, and a display interaction module is arranged in the external control module; the electromagnetic field, ultrasonic waves and medicine assistance are combined, the synergistic effect of multiple treatment means is achieved, the treatment effect on osteoporosis is improved, and compared with a single treatment mode, the bone mineral density can be more rapidly and effectively increased, and the treatment period can be shortened.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

To provide methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS).SOLUTION: Methods are provided for treating PsA or axSpA using an IL-17 antagonist, such as an IL-17 antibody, such as secukinumab. Also provided herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.SELECTED DRAWING: None

The invention belongs to the technical field of brain glioma markers, and particularly relates to application of IGFBP2 in diagnosis and immunotherapy of glioblastoma. According to the invention, single cell sequencing data analysis reveals that CD47 in GBM is closely associated with an anoxic microenvironment, and meanwhile, it is proved that combined application of the anti-IGFBP2 and anti-CD47 antibodies can significantly improve the curative effect of CD47 targeted therapy. According to the research, the IGFBP2 is determined as a potential biomarker for predicting the anti-CD47 treatment response of the GBM patient for the first time, and a new thought is provided for overcoming the anti-CD47 drug resistance through a combined treatment strategy.

Methods for correlating a genetic variant with intraretinal fluid as a marker of response to anti-VEGF therapy in age-related macular degeneration (AMD). Further methods for correlating a genetic variant with visual acuity, anatomical outcomes, or treatment frequency are disclosed herein. The genetic variants identified were found in a non-gene region on the X chromosome p.22.3 in the MICOM gene in the NTRK3 gene and in the ANK2 gene.

The invention belongs to the technical field of biomarkers, and particularly relates to detection for predicting responsiveness of colorectal cancer patients to cetuximab targeted therapy. The invention provides a novel lipid biomarker Cer d (18: 1 / 26: 0) and a corresponding detection method, aiming at solving the technical problems that the EGFR activation state cannot be directly reflected only by detecting gene mutation of downstream pathways such as KRAS / BRAF and the like, the detection method is large in invasiveness, high in cost and the like in the prior art, and the invention provides the novel lipid biomarker Cer d (18: 1 / 26: 0) and the corresponding detection method. The content of Cer d (18: 1 / 26: 0) in peripheral plasma of a colorectal cancer patient is detected, and the treatment responsiveness of the patient is judged according to a preset threshold value. Experimental results show that the content of Cer d (18: 1 / 26: 0) in tumors and plasma of CRC patients is remarkably increased, and the Cer d is closely related to the treatment effect of cetuximab. According to the scheme provided by the invention, the operation is simple and convenient, the wound is small, dynamic monitoring can be realized, and cetuximab treatment can be guided more accurately.

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

The invention discloses an HIV-1 infected person pre-treatment drug resistance analysis system based on drug resistance sequence determination, and belongs to the technical field of medical detection. The invention discloses a drug resistance sequence determination-based drug resistance analysis system for an HIV-1 infected person before treatment. The system comprises a sample acquisition and processing module, a drug resistance sequence determination module, a drug resistance sequence analysis module, a drug resistance phenotype prediction module and a treatment scheme recommendation module. The problem that a treatment scheme is not formulated based on drug resistance analysis in the prior art is solved, drug resistance mutation sites can be accurately recognized through high-throughput sequencing and comparative analysis of HIV-1 drug resistance related gene sequences, the drug resistance degree is graded in combination with clinical guidelines, a scientific basis is provided for follow-up treatment, and the method has good application prospects. According to the method, drug resistance analysis results, drug resistance phenotype prediction and individual characteristics of infected persons are integrated, the most suitable anti-HIV treatment scheme including drug selection, dose adjustment and treatment course suggestion is customized for each infected person, the problem of blind drug use is avoided, and drug resistance generation and transmission are reduced.

The invention discloses a prognosis prediction method and a prognosis prediction system for treating atopic dermatitis patients by dupiliumab, and the method comprises the following steps: acquiring sample data of the patients using dupiliumab, DUPI to treat the atopic dermatitis (AD) in clinical practice; screening out at least 20 characteristic variables most important to AD prognosis prediction from the characteristic variables which can be used for AD prognosis prediction in the patient sample data by capturing the relationship between the characteristic variables and the AD prognosis variables; based on the at least 20 characteristic variables which are most important for AD prognosis prediction, prognosis prediction is conducted on a patient who is about to adopt DUPI to treat AD, and a prognosis prediction result of the patient is obtained. The prediction accuracy of the method can reach the clinical available level, and the invalid treatment cost can be remarkably reduced.

The present application relates, inter alia, to improved methods of treating solid tumors, including, but not limited to, non-small cell lung cancer ('NSCLC') tumors, gastroesophageal adenocarcinoma ('GEA') tumors, colorectal cancer ('CRC') tumors, and advanced solid tumors of MET gene amplification, using anti-c-Met antibody drug conjugates ('anti-c-Met ADC'). In particular embodiments, the anti-c-Met ADC consists of a c-Met targeting antibody, i.e., vietinirituzumab, conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.

This method for predicting the effectiveness of dupilumab administration to an atopic dermatitis patient comprises a step for measuring the concentration of at least one biomarker in a blood sample derived from the patient before dupilumab administration, wherein: the concentration of the biomarker is an indicator for predicting the effectiveness of the dupilumab administration; and the biomarker is selected from the group consisting of interleukin (IL)-22, C-C Motif Chemokine Ligand (CCL) 20, IL-18, IL-17, Tumor Necrosis Factor (TNF)-α, and C-X-C Motif Chemokine 9 (CXCL9).

The application discloses a kind of radiotherapy combined immunotherapy mouse liver injury model construction method and application, the construction method includes: using pentobarbital drug is anesthetized to mouse by intraperitoneal injection;Fix mouse exposure chest and abdomen;Depilating and marking liver position;Fixed front incisor and tail;In anesthetized state, the light of simulation machine is positioned at the liver area of mouse and illuminated, and the liver area is irradiated field, 100 μL of PD-1 antibody diluent is injected intraperitoneally once 1 day before whole liver irradiation, is injected once every 3 days, obtain radiotherapy combined immunotherapy mouse liver injury model, as animal model is used for screening the drug for preventing and treating liver injury caused by radiotherapy combined immunotherapy, including anti-CD20 antibody and its preparation, can prevent and relieve liver injury, and play an active role in liver disease treatment, further explore the important reference basis that anti-CD20 treatment is applied in liver disease treatment.

This invention discloses the application of ferritin heavy chain 1 (FTH1) inhibitors in the preparation of antitumor drugs. This invention collects pre-treatment FFPE tumor tissue from cancer patients receiving anti-PD-1 / L1 therapy. By integrating transcriptomic and proteomic data from baseline samples, FTH1 is screened as a key candidate molecule for immunotherapy resistance. Experiments demonstrate that FTH1 knockout significantly improves the sensitivity of cancer patients to anti-PD-1 / L1 immunotherapy and effectively inhibits tumor growth; conversely, FTH1 overexpression leads to resistance to anti-PD-1 / L1 immunotherapy. This invention can be applied to the development or preparation of antitumor drugs.

The invention relates to an application of an 18S rRNA m7G modified inhibitor in sensitization of PD1 in treatment of liver cancer. Through a large number of in-vivo and in-vitro experiments, it is clear that WBSCR22-mediated 18S rRNA m7G modification serves as a cancer promoting factor of liver cancer, and high expression and high modification level of the WBSCR22-mediated 18S rRNA m7G modification are closely related to tumor metastasis and poor prognosis. Through targeting WBSCR22 mediated 18S rRNA m7G modification, tumor migration can be inhibited, an immune microenvironment can be remodeled, generation of mtROS is promoted, and the expression level of inflammatory factors is improved, so that I-type interferon response caused by a cGAS-STING signal channel is activated, and the curative effect of anti-PD-1 treatment is remarkably improved. The invention has important practical significance for solving the problems of clinical curative effect difference and prognosis evaluation blank among individuals and better realizing accurate treatment. A new drug treatment target is provided for human to treat liver cancer, so that a new direction is provided for subsequent drug research and development, clinical treatment and the like, and extremely high social value and market application prospects are achieved.